Table 5 Clinical characteristics of patients in AA group and non-AA group
Variable | AA group | non-AA group | p-value |
|---|---|---|---|
Number of patients, n (%) | 81 (76.4%) | 25 (23.6%) | Â |
Age at transplantation, years | 48 (45–52) | 51 (36–55) | 0.985 |
Age at UTUC, years | 56 (51–60) | 59 (44–68) | 0.350 |
Time to UTUC, months | 89 (47.5–134) | 125 (53–177.5) | 0.132 |
Male/female ratio | 10/71 | 7/18 | 0.120 |
Smoking history, n (%) | 3 (3.7%) | 1 (4.0%) | 0.946 |
Symptoms, n (%) | Â | Â | Â |
Ipsilateral hydronephrosis | 69 (85.2%) | 21 (84.0%) | 1.00 |
Hematuria | 67 (82.7%) | 20 (80%) | 0.991 |
Tumor staging, n (%) | Â | Â | 0.135 |
T ≥ 2 | 38 (46.9%) | 16 (64.0%) |  |
T < 2 | 43 (53.1%) | 9 (36.0%) |  |
Lymph node staging, n (%) | Â | Â | 0.154 |
 N +  | 2 (2.5%) | 3 (12.0%) |  |
 N0 | 79 (97.5%) | 22 (88.0%) |  |
Tumor grade, n (%) | Â | Â | 0.142 |
 G3 | 35 (43.2%) | 15 (60.0%) |  |
 G1/G2 | 46 (56.8%) | 10 (40.0%) |  |
Multifocality, n (%) | 56 (69.1%) | 11 (44.0%) | 0.023 |
Location, n (%) | Â | Â | 0.104 |
 Renal pelvis only | 19 (23.5%) | 5 (20.0%) |  |
 Ureter only | 21 (25.9%) | 12 (48.0%) |  |
 Pelvis and ureter | 41 (50.6%) | 8 (32.0%) |  |
Concomitant BC, n (%) | 27 (33.3%) | 6 (24.0%) | 0.378 |
Contralateral recurrence, n (%)* | 33 (45.8%) | 2 (9.1%) | 0.002 |
Bladder recurrence, n (%)# | 19 (35.2%) | 5 (26.3%) | 0.479 |